News | January 08, 2026
Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Subscribe To Our Newsletter & Stay Updated
